PV Bulletin

Clinical investigations: compiling a submission

Guidance for manufacturers on submitting clinical investigation proposals for medical devices in the UK has been updated.

Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

The guidance now specifies that documentation for clinical investigation submissions must include comprehensive safety and performance data to meet MHRA assessment requirements.

Why it matters

This update ensures compliance with the UK Medical Device Regulations 2002, impacting the readiness of clinical safety teams to submit accurate and complete safety data, which is essential for the assessment and approval of clinical investigations.

Action needed

Manufacturers must review and align their safety data compilation processes with the updated MHRA guidance to ensure that all necessary information is included in clinical investigation proposals.

Relevant for
Regulatory Intelligence LeadPV Quality Lead
Processes impacted
Inspection Readiness
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guidance
Policy status
revised
Publication date
2026-08-06
Policy change
This guidance for manufacturers on submitting clinical investigation proposals for medical devices was updated to clarify documentation requirements. The update focuses on the submission of safety and performance data for MHRA assessment.

Key changes

Clarified safety data requirements for device clinical investigation submissions; updated submission process for MHRA assessment.

Affected workflows

Inspection Readiness

Responsible groups

Regulatory AffairsPharmacovigilance OperationsClinical Safety

PV impact

The revised guidance dictates how manufacturers must prepare and submit safety data for medical device clinical investigations in the UK. This impacts clinical safety teams' processes for compiling safety reporting and clinical data for MHRA review, ensuring compliance with the UK Medical Device Regulations 2002.

View regulator source

Source document details

Exact policy details

Clinical investigation submission requirements
Documentation must include certain information when applying for approval for a clinical investigation.
Applies to: Manufacturers of medical devices undertaking clinical investigations.
This guidance will help manufacturers to submit the correct information. · p. 1 · High · Source
Updates on clarification of certain standards
Clarified points around software standard IEC 62304, device labeling, essential requirements, risk analysis, and cover letter.
Applies to: Manufacturers submitting clinical investigation proposals.
Updates to the 'Submitting a clinical investigation proposal for MHRA assessment' document. · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Aug 6, 2026

Full briefing

Practical implication

Manufacturers must review and align their safety data compilation processes with the updated MHRA guidance to ensure that all necessary information is included in clinical investigation proposals.

The Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance regarding documentation requirements for clinical investigations. This includes clarity on safety data needed for the assessment of medical devices, affecting the processes of clinical safety teams responsible for compiling safety reporting and clinical data for MHRA review.

What changed: The guidance now specifies that documentation for clinical investigation submissions must include comprehensive safety and performance data to meet MHRA assessment requirements.

Why it matters: This update ensures compliance with the UK Medical Device Regulations 2002, impacting the readiness of clinical safety teams to submit accurate and complete safety data, which is essential for the assessment and approval of clinical investigations.

Practical implication: Manufacturers must review and align their safety data compilation processes with the updated MHRA guidance to ensure that all necessary information is included in clinical investigation proposals.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Urgent Withdrawal of Reusable da Vinci S and Si Instruments Due to Cable Degradation

Urgency: High

Healthcare facilities must isolate the affected instruments and notify Intuitive Surgical for returns while preparing for potential delays in surgical procedures due to instrument replacements.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward